Latest California Healthline Stories
KHN On NPR: The Uniquely American Problem Of High Prescription Drug Costs
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discussed drug costs with Scott Simon, the host of NPR’s Weekend Edition on Saturday, Feb. 10. This is a transcript of that conversation.
Podcast: KHN’s ‘What The Health?’ There’s A Really Big Health Bill In That Budget Deal
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump’s upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called “The United States of Care.”
As States Target High Drug Prices, Pharma Targets State Lawmakers
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits, though their efforts fell short in California, which passed a drug transparency bill in 2017 despite massive opposition from drugmakers.
Podcast: KHN’s ‘What The Health?’ The State Of The (Health) Union
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump’s promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
Big Pharma Greets Hundreds Of Ex-Federal Workers At The ‘Revolving Door’
A KHN data analysis finds that the door of opportunities connecting Capitol Hill, the federal government and the drug industry likely spins in Big Pharma’s favor.
University Under Fire For Off-The-Grid Herpes Vaccine Experiments
Southern Illinois University’s ethics panel launches “full” inquiry into herpes vaccine experiments on human subjects that took place offshore and in the U.S. without proper oversight by one of its professors, who has since died.
Hospital Honchos Hone New Message In Wake Of Opioid Crisis: Expect Pain
“We really do have a lot of responsibility and culpability,” says one hospital official who is part of a working group trying to address the opioid epidemic. Patients have to expect more pain after surgery and understand the risk of addiction, says another doctor.
J.P. Morgan Health Conference All About The Deals Amid Uncertainty For Millions
The lofty ideas floated and billion-dollar deals sealed at J.P. Morgan’s elite annual conference stand in stark contrast to the uncertainty that clouds health care outside its confines.
Fallout From ‘Nuclear Button’ Tweets: Sales Of Anti-Radiation Drug Skyrocket
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Korea’s Kim Jong-un.
Facebook Live: It’s 2018, Can Big Pharma Hold The Line Against Pricing Controls?
In this Facebook Live chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.